SGLT2 Inhibition, Choline Metabolites, and Cardiometabolic Diseases: A Mediation Mendelian Randomization Study. Xu M, Zheng J, Hou T, Lin H, et al. Diabetes Care 2022;45:2718-2728.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Xu M, Zheng J, Hou T, Lin H, et al. SGLT2 Inhibition, Choline Metabolites, and Cardiometabolic Diseases: A Mediation Mendelian Randomization Study. Diabetes Care 2022;45:2718-2728.
PMID: 36161993